Welcome to our dedicated page for Third Harmonic Bio news (Ticker: THRD), a resource for investors and traders seeking the latest updates and insights on Third Harmonic Bio stock.
Third Harmonic Bio Inc (THRD) is a clinical-stage biopharmaceutical company advancing oral KIT inhibitors to treat mast cell-driven inflammatory diseases. This page provides official updates on clinical trials, research breakthroughs, and corporate developments essential for tracking therapeutic progress in dermal, respiratory, and gastrointestinal conditions.
Investors and researchers will find curated news about THB335 Phase 1 studies, regulatory milestones, and scientific partnerships. Content spans clinical data announcements, intellectual property updates, and leadership insights into KIT inhibition strategies. All materials are sourced from verified releases to ensure accuracy.
Regularly updated with non-promotional information, this resource serves as a definitive hub for monitoring Third Harmonic Bio’s progress in developing precision therapies. Bookmark this page or check back frequently for structured updates on one of biopharma’s most focused approaches to inflammatory disease treatment.
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, announced that its CEO, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 7:30 a.m. ET.
The event will be webcast live on the Third Harmonic Bio website, with a replay available for 90 days post-event.
The company focuses on developing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases.
Third Harmonic Bio (Nasdaq: THRD) announced its Q1 2024 financial results and business updates. The U.S. FDA cleared its IND application for THB335, enabling a Phase 1 clinical trial focusing on chronic spontaneous urticaria. Results are expected in the first half of 2025. The company strengthened its leadership, appointing Christopher J. Dinsmore, Ph.D., as Chief Scientific Officer, Dennis Dean, Ph.D., as Chief Non-Clinical Development Officer, and promoting Jennifer Dittman to Chief Development Operations Officer. Financially, the company reported cash and equivalents of $262.8 million, decreased R&D expenses to $6.2 million, and G&A expenses to $5.1 million. Net loss decreased to $7.9 million from $9.1 million a year earlier.
FAQ
What is the current stock price of Third Harmonic Bio (THRD)?
What is the market cap of Third Harmonic Bio (THRD)?
